checkpoint inhibitor
Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis
... FDG-PET CT has also been investigated in checkpoint inhibitor-associated gastrointestinal toxicities. Lang et al. prospectively evaluated 100 patients treated with ipili- mumab for melanoma, and had PET-CT ...
7
Search Terms: adverse events, immune checkpoint inhibitor, myasthenia gravis
... Diagnosing myasthenia gravis is often straightforward as symptoms are quite characteristic, including fluctuation of ocular or bulbar symptoms and/or weakness of neck and proximal limb muscles without sensory deficits ...
41
Characteristics and treatment of new onset arthritis after checkpoint inhibitor therapy
... immune checkpoint inhibitor; IRAEs, immune-related adverse events; HLA, human leukocyte antigen; MS, musculoskeletal; MSI, musculoskeletal inflammation; ND, not determined; PET-CT, positron emission ...
7
Dual checkpoint inhibitor-associated eosinophilic enteritis
... advanced melanoma. The median time to increase in eo- sinophil count was 3.0 months after the first cycle of therapy, with peak eosinophilia (median peak 1000/ mm 3 ) occurring after a median of 6.4 months. Notably, no ...
5
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
... immune checkpoint inhibitor combinations in the murine gli- oma ...immune checkpoint inhibitor combinations in subcutaneous murine glioma models and subsequently validated the results in ...
14
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis
... Hypophysitis is a well-recognized immune-related compli- cation of immune checkpoint inhibitor cancer therapies [1]. The anti-cytotoxic T-lymphocyte- associated protein 4 (CTLA-4) monoclonal antibody (mAb) ...
5
Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
... Immune checkpoint inhibitor (ICI) therapy has revolution- ized cancer treatment. Its use has increased on a broad scale over the past decade, with promising outcomes. In parallel, the incidence of ...
11
<p>Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p>
... Abstract: During malignant transformation, a growing body of mutations accumulate in cancer cells which not only drive cancer progression but also endow cancer cells with high immunogenicity. However, because one or ...
12
Polymyalgia rheumatica like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature
... IL-6 inhibitor tocilizumab after failing repeated efforts to reduce GC dose to the standards generally utilised in idiopathic ...of checkpoint inhibitor therapy, and require prolonged ...
5
Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
... combination checkpoint inhibitor therapy (dosing regimen: ipilimumab 3 mg/kg three weekly, nivolumab 1 mg/kg three weekly) after two melanoma deposits had been resected from his ...immune checkpoint ...
5
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
... to checkpoint inhibitors despite the tumor har- boring homozygous loss of function mutations in STK11 and being PD-L1 protein expression negative by immu- ...to checkpoint inhibitor therapies and the ...
5
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
... Immune checkpoint inhibitors, including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) inhibitors, represent an effective treatment modality for multiple ...benefits, ...
7
Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis
... [12]. Checkpoint inhibitor treatment increased the numbers or activa- tion state of at least one immune cell population in seven experiments but decreased the population examined in one and had no effect in ...
19
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
... Case presentation: We present two cases of metastatic melanoma treated with nivolumab and pembrolizumab (anti PD-1). Both patients developed acute interstitial nephritis during immune checkpoint therapy. We ...
5
Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
... Figure 3 CT of a patient who improved without corticosteroid serial chest CT images of NS-4 patient who did not receive corticosteroid. (A) Chest CT before administration of immune checkpoint inhibitor ...
8
A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report
... PD-1 inhibitor, with or without ipilimumab, a CTLA-4 inhibitor, provides durable responses for some patients who have failed one or more platinum-containing therapy ...a checkpoint inhibitor ...
6
Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury
... We have described three histopathologically distinct cases of steroid-resistant, anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity with overlapping clin- icopathological characteristics. In each ...
9
Molecular imaging biomarkers for immune checkpoint inhibitor therapy
... immune checkpoint inhibitor; IHC: immunohistochemistry; IL2: interleukin-2; irAE: immune-related adverse event; LAG-3: lymphocyte activation gene 3; mAb: monoclonal antibody; MDSC: myeloid-derived ...
11
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
... Patients and methods: We prospectively collected clinical and laboratory data of 56 non-small cell lung cancer patients treated with a checkpoint inhibitor. The aim was to identify baseline parameters ...
8
The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis
... OR (“Immune checkpoint” [All Fields]) OR (“Immune checkpoint inhibitor” [All Fields]). We used this search strategy to search PubMed (https://www.ncbi.nlm.nih.gov/ pubmed), Embase ...
15